Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Francardo, Veronica ^a   Cenci, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Animal models; Dopamine replacement therapy; Genetic models; Motor complications; Striatum

Indexed keywords

ALPHA SYNUCLEIN; AMANTADINE; BENSERAZIDE; BUSPIRONE; DOPAMINE RECEPTOR; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDOPAMINE;

ALPHA SYNUCLEIN GENE; ARTICLE; CELL DIFFERENTIATION; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; DYSKINESIA; ENZYME ACTIVITY; GENE; GENE DELETION; GENE OVEREXPRESSION; GENETIC MODEL; LEUCINE RICH REPEAT KINASE 2 GENE; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMAL MODELS; DOPAMINE REPLACEMENT THERAPY; GENETIC MODELS; MOTOR COMPLICATIONS; STRIATUM;

ANIMALS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MICE; OXIDOPAMINE; PARKINSON DISEASE; TYROSINE 3-MONOOXYGENASE;

EID: 84887971792     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70008-7     Document Type: Article

References (30)

1. Manson A, Stirpe P, Schrag A Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2012, 2:189-198.
2. Hagell P, Cenci MA Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res Bull 2005, 68(1-2):4-15.
3. Cenci MA Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 2007, 30(5):236-243.
4. Cenci MA, Konradi C Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 2010, 183:209-233.
5. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136(Pt 8):2419-2431.
6. Lane EL, Winkler C, Brundin P, Cenci MA The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol Dis 2006, 22(2):334-345.
7. Iderberg H, Francardo V, Pioli EY Animal models of L-DOPA-induced dyskinesia: an update on the current options. Neuroscience 2012, 211:13-27.
8. Cenci MA, Whishaw IQ, Schallert T Animal models of neurological deficits: how relevant is the rat?. Nat Rev Neurosci 2002, 3(7):574-579.
9. Cenci MA, Lee CS, Bjorklund A L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998, 10(8):2694-2706.
10. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002, 15(1):120-132.
11. Winkler C, Kirik D, Bjorklund A, Cenci MA L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002, 10(2):165-186.
12. Dekundy A, Lundblad M, Danysz W, Cenci MA Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007, 179(1):76-89.
13. Lundblad M, Picconi B, Lindgren H, Cenci MA A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004, 16(1):110-123.
14. Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis 2011, 42(3):327-340.
15. Thiele SL, Warre R, Nash JE Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease. J Vis Exp 2012, (60).
16. Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002, 22(3):1054-1062.
17. Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia. Exp Neurol 2005, 194(1):66-75.
18. Fasano S, Bezard E, D'Antoni A, Francardo V, Indrigo M, Qin L, et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 2010, 107(50):21824-21829.
19. Pavon N, Martin AB, Mendialdua A, Moratalla R ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 2006, 59(1):64-74.
20. Alcacer C, Santini E, Valjent E, Gaven F, Girault JA, Herve D Galpha(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 2012, 32(17):5900-5910.
21. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 2007, 27(26):6995-7005.
22. Santini E, Valjent E, Fisone G mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter. Cell Cycle 2010, 9(14):2713-2718.
23. Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 2009, 66(6):603-613.
24. Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier DJ, et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 2010, 107(33):14845-14850.
25. Smith GA, Heuer A, Dunnett SB, Lane EL Unilateral nigrostriatal 6-hydroxy-dopamine lesions in mice II: predicting L-DOPA-induced dyskinesia. Behav Brain Res 2012, 226(1):281-292.
26. DiCaudo C, Riverol M, Mundinano IC, Ordonez C, Hernandez M, Marcilla I, et al. Chronic levodopa administration followed by a washout period increased number and induced phenotypic changes in striatal dopaminergic cells in MPTP-monkeys. PLoS One 2012, 7(11):e50842.
27. Espadas I, Darmopil S, Vergano-Vera E, Ortiz O, Oliva I, Vicario-Abejon C, et al. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol Dis 2012, 48(3):271-281.
28. Berthet A, Bezard E, Porras G, Fasano S, Barroso-Chinea P, Dehay B, et al. L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. J Neurosci 2012, 32(2):681-691.
29. Ding Y, Restrepo J, Won L, Hwang DY, Kim KS, Kang UJ Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis 2007, 27(1):11-23.
30. Ding Y, Won L, Britt JP, Lim SA, McGehee DS, Kang UJ Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A 2011, 108(2):840-845.